Seattle Genetics is a biotechnology company, that was started in 1998. This company is headquartered in Bothell, a suburb of Seattle, in Washington state. They are focused on developing antibody-based therapies that can be used to treat cancer. It is currently the industry leader in antibody-drug conjugates, also known as ADCs.
The ADCs is a technology that has been designed to target the ability of the antibodies to help deliver cell-killing agents directly into the cancer cells. It is also able to save all the non-targeted cells which can help reduce the toxic effects that traditional chemotherapy usually causes.
Clay Siegall has a BS in Zoology from the University of Maryland, as well as a Ph.D. in Genetics from George Washington University. He is a trained scientist, who chose to focus on targeted cancer therapies. He worked at the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997. Before he moved to the National Cancer Institute from 1998 to 1991. Then he co-founded Seattle Genetics in 1998. Clay has written over 70 publications, and also hold numerous patents.
Clay Siegall is the President, Chief Executive Officer, and Chairman of the Board. He built the company on the foundation of scientific innovation, rigorous research, as well as drug developmental practices, that are centered on the passion of helping cancer patients. Over the years he has guided the company to its current leadership in the development of antibody-drug conjugates.
Seattle Genetics has also entered into many strategic licenses for their ADC technology. Some of these licenses include Genentech, AbbVie, GlaxoSmithKline, and Pfizer. All of these licenses have generated more than $325 million in revenue. Across many collaborator programs, there are more than 20 ADCs that are in clinical development that are currently using Seattle Genetics’ technology.